A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Epelsiban (Primary)
- Indications Adenomyosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Oct 2016.
- 06 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2016.
- 06 Jan 2017 Status changed from suspended to withdrawn prior to enrolment.